Other

Yung Shin Pharm. Ind. Co., Ltd.

Yung Shin Pharmaceutical Industrial Co. Ltd.

Yen-Ling Yi

Chiung-Ju Tsai

Fang-Yu Lee

Shan-Chiung Chen

Bin-Ken Chen

Shih-Lung Chang

Wei-Liang Lin

Chia-Chun Lee

Man-Hsin Wang

A pharmaceutical composition for improving wound healing is provided. The pharmaceutical composition includes (a) hyaluronic acid or its derivation, (b) an effective amount of an active ingredient; and optionally (c) pharmaceutically acceptable carriers and/or excipients. In one embodiment, the active ingredient includes vitamin. In another embodiment, the active ingredient includes acexamic acid. In still another embodiment, the pharmaceutical composition can further comprise sorbic acid.

Pharmaceutical composition for improving wound healing or prophylactically preventing or inhibiting scar formation

The present invention provides pharmaceutically acceptable salts having local anesthetic and anti-inflammatory activities. The preferred pharmaceutically acceptable salt is a diclofenac salt of lidocaine. Diclofenac is a non-steroidal anti-inflammatory drug ('NSAID'). Lidocaine is a local anesthetic. Other NSAID (except the salicylic acid derivatives of NSAID) can be used to replace diclofenac and/or other local anesthetics can be used to replace lidocaine. The pharmaceutically acceptable salts are crystalline compounds, which are distinctively different from either the NSAID alone or the local anesthetic alone, as indicated by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), High Performance Liquid Chromatography (HPLC) and Fourier-Transformed Infrared Spectroscopy (FTIR) analyses. These pharmaceutically acceptable salts are suitable for use in topical treatment or parenteral injection to treat patients with localized pain, including muscle pain, joint pain, pain associated with herpes infection, and wound pain (such as surgical wound, burn wound etc.).

Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same

The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.

Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection

Growing community of inventors

Taichung, Taiwan

Yen-Ling Yi